Conventionally, an individual’s risk of developing CVD is assessed through their self-reported family history and lifestyle factors, such as physical activity levels, diet and smoking. However, this doesn’t consider their genetic susceptibility to CVDs.
When an individual is classed as an intermediate risk based on their lifestyle factors, it can be hard to determine if they will progress onto developing CVDs, which is where genotyping could become extremely useful.
TYPE III Hyperlipoproteinemia, Atrial Fibrillation, Coronary Artery Disease, Hypertension, Myocardial Infarction, Peripheral Arterial Disease, Sickle Cell Anaemia.
Beta Blocker Efficiency, Beta Blockers and LVEF Response, Metoprolol metabolism, Warfarin Sensitivity, Clopidogrel Metabolism, Verapamil and QTC Interval, Verapamil vs Atenolol, Simvastatin Uptake, Perindopril Metabolism, Caffeine Sensitivity.
Triglycerides, HDL Cholesterol, LDL Cholesterol and Gene X (Cholesterol lowering polymorphism).
Factor V Leiden, Prothrombin G20210A and MTHFR Variant.
Patients with a family history of CVD.
Patients with existing cardiac conditions and would like to learn more about their conditions.
Patients who are on oestrogen therapy from combined oral contraceptives or HRT, or at risk of developing DVT.
Patients who are about to start medicating or currently on a treatment plan with reported side effects.
Anyone who would like to be more certain about their future cardiac health and make preventative lifestyle and behavioural changes.
The reports enable you to strengthen your patients' informed consent by giving them full knowledge of the potential consequences regarding their lifestyle choices, treatment options and the possible risks and benefits.
The Heart DNA Test helps you suggest early interventions by identifying genetic risk factors for a range of conditions.
Boost patients confidence in their prescribed treatment and improve adherence to medical advice, by uncovering genetic insights that changes the clinical dialogue from a population level advice to a more personal one.
Have a more objective risk assessment by combining the patient's genetic risk profile and self-reported environmental factors. No report would ever be released without your prior review and context provision. The final decision is always yours.
Our pharmacogenetics panel predicts patients drug responses, reducing prescriptions of medication that is ineffective or causes adverse side effects.
Rightangled's Platform delivers a new way to personalise cardiac care by giving you access to genetic information alongside lifestyle and environmental risk factors for your patients online. This information will help you build a better risk profile of your patients while adding your assessment onto the report in an easy and streamlined way.
The whole process is online. you can create an account, fill in your speciality details, set your fees and access your dashboard for all our learning resources.
Place orders for individual patients or make bulk orders and receive discounts based on volumes.
Access your patient results and self-reported answers to Qrisk and JBS 3 questionnaire, and make online reviews. Once completed you can sign off the reports to your patients online.
Patients can book appointments with you directly from their dashboard as well.
The kits are barcoded with unique IDs which will assign your patients to your account.
As an individual, you don't really care what happens to the rest of the population, unless it's about you specifically... Genomics Medicine lends itself to that
Dr. Sibtain Anwar
Cardiac Anaesthesia Consultant
We also provide you with a clinical reporting manual to review cumulative risk profile, and an on going support to answer all your questions from our network of leading geneticists.
We translate clinical research on genetics and FDA adopted interpretation guidelines into practical formats to help you build your personalised advice to your patient.
Shukla, H., Mason, J. L., & Sabyah, A. (2018). A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs. American Journal of Cardiovascular Drugs, 18(4), 259–269.
Shukla, H., Mason, J. L., & Sabyah, A. (2018). Identifying genetic markers associated with susceptibility to cardiovascular diseases. Future Science OA, https://doi.org/10.4155/fsoa-2018-0031
It's time of precision medicine.Become a partner